Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral session: Breast cancer

22MO - Efficacy and safety of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer (mTNBC) by baseline HER2 expression level: Subgroup analysis from a phase IIb trial


03 Dec 2022


Mini Oral session: Breast cancer


Tumour Site

Breast Cancer


Fei Ma


Annals of Oncology (2022) 33 (suppl_9): S1438-S1440. 10.1016/annonc/annonc1120


B. Xu1, F. Ma1, S. Wang2, Z. Tong3, W. Li4, X. Wu5, X. Wang6, T. Sun7, Y. Pan8, H. Yao9, X. Wang10, T. Luo11, J. Yang12, X. Zeng13, W. Zhao14, X.J. Cong15, N. Wang16, C. Xu16, J.J. Chen16

Author affiliations

  • 1 Oncology Department, Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, 100021 - Beijing/CN
  • 2 Oncology Department, Sun Yat-sen University Cancer Center, 510060 - Guangzhou/CN
  • 3 Department Of Breast Cancer Pathology, TMUCIH - Tianjin Medical University Cancer Institute and Hospital, 300060 - Tianjin/CN
  • 4 Oncology Department, The First Hospital of Jilin University, 130021 - Changchun/CN
  • 5 Oncology Department, Hubei Cancer Hospital, 430079 - Wuhan/CN
  • 6 Oncology Department, Zhejiang Cancer Hospital - Cancer Research Institute, 310022 - Hangzhou/CN
  • 7 Oncology Department, Liaoning Cancer Hospital & Institute, 110042 - Shenyang/CN
  • 8 Oncology Department, Anhui Provincial Hospital, 230001 - Hefei/CN
  • 9 Oncology Department, 2nd Affiliated Hospital of Sun Yat-sen University, 510308 - Guangzhou/CN
  • 10 Oncology Department, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, 310016 - Hangzhou/CN
  • 11 Oncology Department, West China School of Medicine/West China Hospital of Sichuan University, 610041 - Chengdu/CN
  • 12 Oncology Department, The First Affiliated Hospital of Xi’an Jiaotong University, 710049 - Xi’an/CN
  • 13 Oncology Department, Chongqing Cancer Hospital, 400000 - Chongqing/CN
  • 14 Oncology Department, Chinese PLA General Hospital (301 Military Hospital), 100853 - Beijing/CN
  • 15 Biometrics Department, Everest Medicines, 200040 - Shanghai/CN
  • 16 Medical Department, Everest medicines, 200041 - shanghai/CN


Login to access the resources on OncologyPRO.

Abstract 22MO


About 30-40% of mTNBC patients (pts) have tumors with HER2 low expression, which might be a potential target of some novel anti-HER2 agents. Sacituzumab govitecan (SG), a novel Trop2-targeted antibody-drug conjugate, has been approved for second line onwards mTNBC treatment by Singapore and NMPA recently. To better understand the role of SG in the treatment of Chinese mTNBC with different HER2 expression level, subgroup data of EVER-132-001 were analyzed.


EVER-132-001 is a multicenter, single-arm, Phase IIb study of SG in Chinese pts with mTNBC who received at least two prior systemic treatments. In this subgroup analysis, HER2 status of the most recent tumor biopsy tissue was evaluated by immunohistochemistry [IHC] and Fluorescence in situ hybridization [FISH] locally. Pts were divided into 2 subgroups: HER2-neg (IHC 0) and HER2-low (IHC 1+, or IHC 2+ and FISH negative). Efficacy and safety of SG across subgroups were analyzed and reported.


Of the 80 mTNBC pts enrolled, there were 43 reported HER2-neg and 37 HER2-low (IHC 1+, n=20). Demographics, baseline disease characteristics and prior anticancer treatments were generally balanced across the two subgroups. The median number of prior systemic therapies was 4 in both subgroups. According to Independent Review Committee assessment, objective response rate was 41.9% (95% confidence interval [CI] 27.01-57.87) in HER2-neg group and 35.1% (95% CI 20.21-52.54) in HER2-low group, and clinical benefit rate was 46.5% (95% CI 31.18-62.35) and 40.5% (95% CI 24.75-57.90), respectively. Median progression free survival was 6.9 months (95% CI 4.21-NA) in HER2-neg and 5.5 months (95% CI 2.83-NA) in HER2-low. SG-related CTCAE Grade ≥3 treatment-emergent adverse events reported were similar (69.8% vs 73.0%), and the most common ones both were neutrophil count decreased (62.8% vs 62.2%), white blood cell count decreased (44.2% vs 54.1%), and anemia (23.3% vs 18.9%).


SG showed comparable anti-tumor activity in both HER2-neg and HER2-low subgroups of later line Chinese mTNBC pts. The safety profile was consistent across two subgroups and both manageable.

Clinical trial identification

NCT04454437, First posted: July 1, 2020.

Editorial acknowledgement

Legal entity responsible for the study

Everest Medicines.


Everest Medicines.


X.J. Cong, N. Wang, C. Xu, J.J. Chen: Financial Interests, Personal, Other, employee: Everest Medicines. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.